A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance

Cancer

Volumn 103, Issue 3, 2005, Pages 451-461

  Kuehn, Thorsten ^a,h   Bembenek, Andreas ^b   Decker, Thomas ^c   Munz, Dieter Ludwig ^d   Sautter Bihl, Marie Luise ^e   Untch, Michael ^f   Wallwiener, Diethelm ^g  

^a Interdisciplinary Breast Center   (Germany)

^b Section of Pathology   (Germany)

^c HELIOS Klinikum Berlin   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h Frauenklinik ^*  (Germany)

Author keywords

Breast carcinoma; Consensus panel; Quality assurance; Sentinel lymph node biopsy

Indexed keywords

BLUE DYE; DYE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

BREAST CARCINOMA; CLINICAL PATHWAY; CONSENSUS; EARLY CANCER; EVIDENCE BASED MEDICINE; FOLLOW UP; GERMANY; GYNECOLOGY; HEALTH CARE QUALITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; JOB PERFORMANCE; LYMPHATIC MAPPING; LYMPHOSCINTIGRAPHY; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; MEDICAL EDUCATION; MEDICAL SOCIETY; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; NUCLEAR MEDICINE; PATHOLOGIST; PATIENT INFORMATION; PATIENT SELECTION; PEROPERATIVE CARE; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY CONTROL; RADIOLOGIST; REPRODUCIBILITY; REVIEW; SCINTILLATION CAMERA; SENTINEL LYMPH NODE BIOPSY; STANDARDIZATION; SURGEON; SURGICAL TECHNIQUE; TRAINING; TREATMENT INDICATION; VALIDATION PROCESS;

BREAST NEOPLASMS; CONSENSUS DEVELOPMENT CONFERENCES; FEMALE; GERMANY; HUMANS; QUALITY ASSURANCE, HEALTH CARE; RADIOPHARMACEUTICALS; SENTINEL LYMPH NODE BIOPSY; SOCIETIES, MEDICAL;

EID: 12744254900     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20786     Document Type: Review

References (53)

1. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21:3357-3365.
2. Sobin LH, Wittekind C, editors. TNM classification of malignant tumors, 6th ed. New York: John Wiley & Sons, 2002.
3. Greene FL, Page D, Fleming I, et al., editors. AJCC cancer staging manual, 6th ed. New York: Springer-Verlag, 2002.
4. Schwartz GF, Guiliano AE, Veronesi U. Proceeding of the consensus conference of the role of sentinel lymph node biopsy in carcinoma or the breast April 19-22, 2001, Philadelphia, PA, USA. Breast J. 2002;8:124-138.
5. McMasters KM, Tuttle TM, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560-2566.
6. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med. 1998;339:941-946.
7. Tafra L, Lannin DR, Swanson MS, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg. 2001;233:51-59.
8. Bergkvist L, Frisell J, Liljegren G, Celebioglu F, Damm S, Thorn M. Multicentre study of detection and false-negative rates in sentinel node biopsy for breast cancer. Br J Surg. 2001;88:1644-1648.
9. Kuehn T, Vogl FD, Helms G, et al. Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol. 2004;30:252-259.
10. Roumen RM, Kuijt GP, Liem IH, van Beek MW. Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection. Br J Surg. 2001;88:1639-1643.
11. Schrenk P, Hatzl-Griesenhofer M, Shamiyeh A, Waynad W. Follow-up of sentinel node negative breast cancer patients without axillary lymph node dissection. J Surg Oncol. 2001;77:165-170.
12. Giuliano AE, Haigh PI, Brennan MB, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18:2553-2559.
13. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546-553.
14. Morrow M, Rademaker AW, Bethke KP, et al. Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. Surgery. 1999;126:714-720.
15. Derossis AM, Fey I, Yeung H, et al. A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Surg. 2001;193:473-478.
16. Cserni G. Tumour histological grade may progress between primary and recurrent invasive mammary carcinoma. J Clin Pathol. 2002;55:293-297.
17. Heuser T, Rink T, Weller E, et al. Impact of the axillary nodal status on sentinel node mapping in breast cancer and its relevance for technical proceeding. Breast Cancer Res Treat. 2001;67:125-132.
18. Cox CE, Bass SS, Boulware D, Ku NK, Berman C, Reintgen DS. Implementation of new surgical technology: outcome measures for lymphatic mapping of breast carcinoma. Ann Surg Oncol. 1999;6:553-561.
19. Cody HS III, Hill AD, Tran KN, Brennan MF, Borgen PI. Credentialing for breast lymphatic mapping: how many cases are enough? Ann Surg. 1999;229:723-726.
20. McMasters KM, Wong SL, Chao C, et al. Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques. Ann Surg. 2001;234:292-299.
21. Sanidas EE, de Bree E, Tsiftsis DD. How many cases are enough for accreditation in sentinel lymph node biopsy in breast cancer? Am J Surg. 2003;185:202-210.
22. Siegel BM, Mayzel KA, Love SM. Level I and II axillary dissection in the treatment of early-stage breast cancer. An analysis of 259 consecutive patients. Arch Surg. 1990;125:1144-1147.
23. Bader AA, Tio J, Petru E, et al. T1 breast cancer: identification of patients at low risk of axillary lymph node metastases. Breast Cancer Res Treat. 2002;76:11-17.
24. Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985;312:674-681.
25. Louis-Sylvestre C, Clough K, Asselain B, et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up. J Clin Oncol 2004;22:97-101.
26. Borgstein PJ, Meijer S, Pijpers RJ, van Diest PJ. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method. Ann Surg. 2000;232:81-89.
27. Klimberg VS, Rubio IT, Henry R, Cowan C, Colvert M, Korourian S. Subareolar versus peritumoral injection for location of the sentinel lymph node. Ann Surg. 1999;229:860-864.
28. Roumen RM, Geuskens LM, Valkenburg JG. In search of the true sentinel node by different injection techniques in breast cancer patients. Eur J Surg Oncol. 1999;25:347-351.
29. Nathanson SD, Wachna DL, Gilman D, Karvelis K, Havstad S, Ferrara J. Pathways of lymphatic drainage from the breast. Ann Surg Oncol. 2001;8:837-843.
30. Maza S, Valencia R, Geworski L, et al. Peritumoural versus subareolar administration of technetium-99m nanocolloid for sentinel lymph node detection in breast cancer: preliminary results of a prospective intra-individual comparative study. Eur J Nucl Med Mol Imaging. 2003;30:651-656.
31. Tanis PJ, Nieweg OE, Valdes Olmos RA, Kroon BB. Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg. 2001;192:399-409.
32. Intra M, Veronesi P, Mazzarol G, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg. 2003;138:309-313.
33. Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000;18:3480-3486.
34. Pendas S, Jakub J, Giuliano R, Gardner M, Swor GB, Reintgen DS. The role of sentinel lymph node biopsy in patients with ductal carcinoma in situ or with locally advanced breast cancer receiving neoadjuvant chemotherapy. Cancer Control. 2004;11:231-235.
35. Schwartz GF, Hortobagyi GN. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer. 2004;100:2512-2532.
36. McMasters KM, Wong SL, Tuttle TM, et al. Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel nodes. Ann Surg. 2000;231:724-731.
37. McCarter MD, Yeung H, Fey J, Borgen PI, Cody HS III. The breast cancer patient with multiple sentinel nodes: when to stop? J Am Coll Surg. 2001;192:692-697.
38. Nieweg OE, Tanis PJ, Kroon BB. The definition of a sentinel node. Ann Surg Oncol. 2001;8:538-541.
39. Wong SL, Edwards MJ, Chao C, et al. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg. 2001;192:684-689.
40. Kennedy RJ, Kollias J, Gill PG, Bochner M, Coventry BJ, Farshid G. Removal of two sentinel nodes accurately stages the axilla in breast cancer. Br J Surg. 2003;90:1349-1353.
41. Cserni G, Amendoeira I, Apostolikas N, et al. Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer. 2003;39:1654-1667.
42. Cserni G. Axillary staging of breast cancer and the sentinel node. J Clin Pathol. 2000;53:733-741.
43. Cserni G. A model for determining the optimum histology of sentinel lymph nodes in breast cancer. J Clin Pathol. 2004;57:467-471.
44. Dowlatshahi K, Fan M, Anderson JM, Bloom KJ. Occult metastases in sentinel nodes of 200 patients with operable breast cancer. Ann Surg Oncol. 2001;8:675-681.
45. Millis RR, Springall R, Lee AH, Ryder K, Rytina ER, Fentiman IS. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer. 2002;86:396-401.
46. Farshid G, Pradhan M, Kollias J, Gill PG. Computer simulations of lymph node metastasis for optimizing the pathologic examination of sentinel lymph nodes in patients with breast carcinoma. Cancer. 2000;89:2527-2537.
47. Lacour J, Le MG, Hill C, Kramar A, Contesso G, Sarrazin D. Is it useful to remove internal mammary nodes in operable breast cancer? Eur J Surg Oncol. 1987;13:309-314.
48. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641-1648.
49. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949-955.
50. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956-962.
51. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539-1569.
52. Sautter-Bihl ML, Hultenschmidt B, Melcher U, Ulmer HU. Radiotherapy of internal mammary lymph nodes in breast cancer. Principle considerations on the basis of dosimetric data. Strahlenther Onkol. 2002;178:18-24.
53. Kinne DW. Staging and follow-up of breast cancer patients. Cancer. 1991;67:1196-1198.